Weather

86°F4:17 PM

Health

1 read

New Health Savings Account Rules Coming in 2026: What El Paso Residents Need to Know

KVIA•Friday, February 20, 2026 at 9:19 AM•Stacker

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

The One Big Beautiful Bill Act introduces significant changes to Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) starting in 2026. More Affordable Care Act marketplace plans will become HSA-eligible, potentially increasing eligible individuals by 10 million. Additionally, direct primary care membership fees will qualify as medical expenses under HSAs, and the annual limit for dependent care FSAs will rise to $7,500. These updates aim to alleviate out-of-pocket healthcare costs for El Paso residents and provide more options for managing medical expenses. It's essential for residents to familiarize themselves with these changes to maximize their healthcare savings.

Key Details: • Starting January 1, 2026, direct primary care memberships can be paid for with HSAs. • Dependent care FSA limits increase to $7,500 per household in 2026. • HSA contribution limits will rise to $4,400 for self-only coverage and $8,750 for family coverage in 2026. • Telehealth services can be covered by high-deductible health plans before meeting the deductible, effective from plans starting January 1, 2025.

healthcare insurance fsa hsa tax

People & Organizations

El PasoDonald Trump

Related Articles

El Paso to Participate in National Prescription Drug Take Back Day This Saturday

This Saturday, April 25, the U.S. Drug Enforcement Administration (DEA) will conduct its 30th National Prescription Drug Take Back Day, providing a crucial opportunity for residents to safely dispose of unused or expired medications. The event will take place from 10 a.m. to 2 p.m. at nearly 4,200 locations across the country, including several in El Paso. This initiative is vital for preventing drug misuse and protecting the environment. Residents are encouraged to participate and help reduce the risk of prescription drug abuse in the community.

Severe Health Risk: Flesh-Eating Bacteria Detected in New York Waters

A dangerous strain of flesh-eating bacteria has been identified in the waters of New York, raising significant health concerns. Individuals who contract this infection face a staggering 20% mortality rate within just 48 hours. This alarming statistic underscores the urgency for public awareness and precautionary measures, especially for those engaging in water activities. Residents are advised to stay informed about local water safety and health advisories to mitigate risks associated with this deadly bacteria.

FDA Fast-Tracks Approval for Psychedelic Drugs in Mental Health Treatment

The FDA has expedited the review process for several psychedelic drugs aimed at treating mental health conditions, including psilocybin for treatment-resistant depression and PTSD. This initiative, part of a pilot program, could significantly reduce the time these treatments take to reach patients. A recent executive order from President Trump mandates the FDA to prioritize these therapies and includes a $50 million investment for state studies on their benefits. As the FDA continues to authorize clinical trials for psychedelics like ibogaine, the potential for these drugs to address the mental health crisis in the U.S. is gaining attention, particularly for veterans and those with severe mental health issues. However, the FDA warns that these substances, classified as Schedule I drugs, will only be available in controlled clinical settings if approved.

FDA Fast-Tracks Psychedelic Drugs for Mental Health Treatments in the U.S.

The FDA has initiated a significant step towards the approval of psychedelic drugs as mental health treatments by issuing national priority vouchers to three companies. These include psilocybin for treatment-resistant depression and methylone for PTSD. This move, part of a pilot program aimed at expediting the review process, is crucial as it could provide new options for patients struggling with severe mental health issues. Additionally, an early phase clinical study of ibogaine for alcohol use disorder has been approved, marking a milestone in psychedelic research. Health officials emphasize the importance of rigorous clinical evidence as these treatments are explored.